We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Obesity, Metabolic Syndrome, and Prediabetes
Center of Excellence
Interested in receiving weekly updates about the Obesity, Metabolic Syndrome, and Prediabetes Center of Excellence?
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Chandrakant Madgaonkar
Jun 08, 2021
In this case, 54y/0, LADA with positive GAD antibodies, and strong family H/O DM , and HBA1c 8%, low BMI, a combination of metformin with DPP–4 inhibitors, or SGLT2 inhibitors, with Vitamin D3 can be considered (in place of insulin); further consider to rule out other auto-immune disorders such as thyroid dysfunction ... etc. Thank you.
Javier Morales
Jun 11, 2021
I have a similar patient with a similar story. Again, intolerance to injectable GLP one therapy and SGL T2 inhibitor therapy resulted in significant and severe dyslipidemia. Currently, and for physiologic replacement and believe it or not, seems to have better glycemic control on Janumet than when on a GLP1 , Possibly due to glucagon suppression. The curious thing was the better glycemic control while on DPP4 Which makes me question his adherence with GLP one. As a rule, I stay way from SUs
Ermir Nelaj
Jun 17, 2021
I would try to treat him ...
Metformin 2 x 100mg/d + SGTL2 inhibitor (dinner) + Gliclaside (MR) 60mg daily
roohi ilyas
Nov 20, 2021
For LADA insulin basal bolus regimen is going to control the sugar. Since diagnosis of diabetes is 10 years old, no benefit from DPP4 inhibitors or GLP1 or piaglitazone etc is going to help.
Apr 20, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Jacqueline
A.
Seiglie
MD, MSc
Chandrakant Madgaonkar
Jun 08, 2021
Javier Morales
Jun 11, 2021
Ermir Nelaj
Jun 17, 2021
roohi ilyas
Nov 20, 2021
Apr 20, 2024
Pending Moderator approval.